Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Benitec — Non-Deal Roadshow (April 2007)
27 slides from Benitec Biopharma's roadshow presentation, Apr 27, 2007
Slide 1: London Investor Briefing
Benite¢, ( LEADER IN GENE SILENCING TECHNOLOGY London Investor Briefing 27 April 2007, Melbourne, Australia: Sue MacLeman CEO Benitec Limited (ASX:BLT) will today present to investors and shareholders at a London investor briefing. "This is an exciting time for Benitec and we are pleased to be able
Slide 2: Benitec Ltd (ASX:BLT) Investor presentation London
Benitec Ltd (ASX:BLT) Investor presentation ‘ondon
Slide 3: Outline
Outline . About RINA Interference Product progress Intellectual property position Capital Structure
Slide 4: Overview
Overview . Pioneers in RNAI since 1997 Royalty generating patent portfolio — seminal patents in DNA-directed RNA interference (ddRNA\) Multiple licensees for commercial and therapeutic uses HIV/AIDS therapeutic is lead therapeutic Developing treatments for commercially attractive, major, life-threat
Slide 5: RNAi therapeutics — a disruptive new platform
RNAi therapeutics — a disruptive new platform . Function RNA Protein RNAI Small Molecules Antibodies
Slide 6: Mechanism of RNA interference (RNAi)
Mechanism of RNA interference (RNAi) 7) dsRNA * Natural mechanism « Rapidly deployed * Highly specific * Catalytic siRNA or Activated RNAI Target Binding Target Destruction y ee TOT ee TO LT TAT rT vet tae, ge ADAAA
Slide 7: Advantages of ddRNAi
Advantages of ddRNAi . Compared with alternative gene silencing technologies eg antisense and siRNA: « Lower cost and ease of preparation « More versatile delivery options « Ability to silence genes in whole organisms (transgenic ddRNAi) * Control expression and timing of gene silencing
Slide 8: RNAi market opportunity
RNAi market opportunity . * RNAi global sales over US$tbn in 2004 * Projected - US$2.5bn by 2010 « Competitive dynamic market environment Figuee 1 Estimated annval worldwide: revenues from RMAL sand marke segments, 4a} Although the market for RNAi is new and relatively aml, eapid growth hae been see
Slide 9: Market Reward for RNAi
Market Reward for RNAi e Benitec, Alnylam, and Sirna featured on BIO 2006 panel as the leading companies worldwide in IP and development of RNAi ALNYLAM PHARNACELIT as af 4-Apir-2007 CYTRX CP as of 4-Ror-2007 Tat / | / / / Elmcyre : | : | 5)—day EMA HSA. ED... sen Lannnannrannnnninniannannmnnnnifter
Slide 10: Licensees and strategic partners
Licensees and strategic partners os) Therapeutic use of ddRNAI * Tacere Therapeutics Inc {signed Sept 06) * Alnylam Pharmaceuticals Inc * CombiMatrix Corp * Revivicor LAlnylam, COM EINAAT REX, Disses the pete /Revivicor Research reagent or transgenic animal product development and sales * Sigma-Aldr
Slide 11: RNAi drug development strategy
RNAi drug development strategy . Sequence-based, broad specificity therapeutics « Select RNAI targets quickly to cover most of patient population- RNAi advantage over smali molecule Prevent generation of drug-resistant diseases * Combination of multiple drugs in a single treatment- ddRNAi advantage
Slide 12: HIV/AIDS stem cell program
HIV/AIDS stem cell program . Fd City of Molecular targets rHIV7-shl-TAR-CCR5RZ a“ Hope cectae * HIV genome * cell-surface receptor * replication machinery Data published in Nature Reviews, PNAS and Molecular Therapy Clinical Development Partner: City of Hape * vector rHIV7-shI-TAR-CCR5RZ was manufac
Slide 13: HIV program — path to clinic
HIV program — path to clinic ) Stem cell therapy for HIV/AIDS lymphoma * HIV/AIDS lymphoma manufactured at City of Hope * RAC submission reviewed at the NIH Sep 2005 * Single site Phase 1 trial at City of Hope Medical Center from Q2 2007 T-Cell therapy for HIV/AIDS * Benitec partnering City of Hope,
Slide 14: AIDS / lymphoma clinical trial design
AIDS / lymphoma clinical trial design . Apheresis ~ Stem-cell enrichment Healthy HIV positive or chemo-responsive AIDS lymphoma patient transduction of CD34" stem cells \ Lentivirai-mediated oS CD34* PBPC GCSF Pool and infuse into patient after 5-day chemotherapy — voadiee Patient follow-up for mark
Slide 15: HCV Program
HCV Program ) Molecular target: Hepatitis C virus genome Published in Nature and Nature Biotech RNAi Therapeutics « Multi-targeting to prevent viral escape * “Cocktail” in one drug Licensed to Tacere Therapeutics Inc Sep 06 Structural Proteins Non-Structural Proteins
Slide 16: Board and senior managers
Board and senior managers o Peter Francis Sue MacLeman Non-exec chairman Extensive experience in CEO Joined pharmaceutical industry in 1991 with technology commercialisation, founder & non- Schering Plough and then with Amgen Inc and exec director of Boron Molecular P/L, Xceed Bristol Myers Squibb P
Slide 17: Business strengthening
Business strengthening . Lower cost model Co-investment and/or licensing Recent successful rights issue raised over $5m Australian-based management team First drug into clinical Phase 1 trial (HIV/AIDS lymphoma) Continue out-licensing IP for target validation and therapeutics Further strengthen worl
Slide 18: Risk and mitigation
Risk and mitigation ) Risks Mitigation « UPSTO re-examination * Capital raising and Nucleonic litigation » Low cost model * Cash position » Strengthened cash position from Promega’s investment (Oct 06) * Renegotiation with CSIRO resulting in more equitable and collaborative relationship + Extra reve
Slide 19: Benitec IP
Benitec IP . Extract from Companies & Markets, Jain PharmaBiotech Aug 2006 RNAI patents —- Among the companies, Alnylam and Benitec have strong patent positions. » On 5 June 2003, Benitec Ltd was granted its core technology patents in the US and the UK + These patents, with priority dating to 1998,
Slide 20: Benitec IP
Benitec IP . “Negotiating the RNAi patent thicket” Nature Biotechnology March 2007 Most of the IP in this area (RNAI) is owned by Benitec, in Melbourne, Australia. Benitec lays claim to a seminal US patent... that describes “genetic constructs for delaying or repressing the expression of a target ge
Slide 21: Intellectual Property
intellectual Property . An industry-leading patent portfolio in RNAI DiA-directed RNA; DINA directed RNAI in tigsue BNAi in mouse model of human in plants cullure and mammals disease (Graham et al) (Graham, Rice et al) (MicCalfrey and Kay) Plant Co-suppression RNA ip nematodes RNAi in Drosophila and
Slide 22: List of Key Patents
List of Key Patents Patent/Applicalion Number Invention Title Inventor(s} 6,573,080 {US} GENETIC CONSTRUCTS FOI DELAYING OF REPRESSING THE EXPRESSION OF A TARGET GENE Graham, Michael V < Rive, Robert N POT AUgONNETIS, (wOSdaH020, AL 2016399 CA 2,223,726, £2 PV2000-3246 (205108) CB GB2S53292 HK 01105
Slide 23: Corporate structure
Corporate structure os) 100.0% 100.0% Benitec Limited ASX:BLT 100.0% 100.0% Benitec Limited UK Benitec Australia Limited RNAi Therapeutics inc. Benitec Inc Benitec LLC
Slide 24: Benitec capital structure
Benitec capital structure ) Shares outstanding 286,648,481 Share price as of 18 April A$0.17 Market capitalisation AS48.7m Options/warrants outstanding 111,363,768 Fully diluted shares 398,012,249 oa BENTTET Feo , as of A-Apr—2007 MBLT.AX MS0-day MA B200-day MA o.2 od o.0 i 60.9 2 540.0 S2o.0 = 3.9
Slide 25: Largest shareholders
10 largest shareholders Sharehoider Dr Christopher Bremner Captain Starlight Nominees Pty Ltd Sigma-Aldrich Pty Limited Promega Corporation National Nominees Limited Citicorp Nominees Pty limited Artemis Trustees Limited <The Whale A/C> Invia Custodian Pty Limited <White A/C> HSBC Custody Nominees (
Slide 26: Compelling opportunity for investment
Compelling opportunity for investment . Opportunity for investors — dynamic area « Undervalued * Royalty generating patent portfolio * Nobel Prize Fire and Mello ~ validation of science » Merck purchase of Sirna for US$1.1bn, 2x market cap Strong IP position * Global rights to human therapeutics Hig
Slide 27: Sue MacLeman
Ne: Sue MacLeman Level 1, 123 Camberwell Rd Hawthorn East Vic 3123 +61 (0) 437211200 [email protected] www.benitec.com